Key Drivers
- Earnings Strength
- Liquidity Pressure
- Debt Build-up
AIAI Summary
Sanofi has moved from a defensive pharma-income name to a potential re-rating story on the back of Dupixent-led growth and upgraded guidance, but with gains still concentrated in a few assets and IFRS/balance-sheet noise limiting margin for error, the stock looks investable only if execution broadens and the mid-45 resistance is broken decisively.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Earnings Strength
- •Liquidity Pressure
- •Debt Build-up
SNY remains highly profitable and cash-generative at a moderate annual valuation, but weaker liquidity, rising leverage, and a large intangible asset base mean the dividend and upside rely on sustained earnings.
Price Behavior
Key Price Behavior Insights:
- •Support Rebound
- •Failed Breakout
- •Range Bound
SNY has stabilized after bouncing from strong support at $42.7–$43.0, but it remains range-bound below $44.9–$45.5 resistance and needs a close above that zone to confirm a breakout.
Late-July push into the mid-$45s quickly reversed, signaling a failed breakout
Sentiment & News
Key News Insights:
- •Outlook raised
- •Pipeline setback
- •Leadership reset
Sanofi's July 2026 story was a mix of stronger-than-expected sales and raised guidance, offset by pipeline setbacks and a broader strategic reset under new leadership.
The news is modestly supportive for sentiment due to strong operating momentum, but pipeline uncertainty and a still-neutral analyst stance may keep upside capped near term
Similar Companies in Healthcare
Other companies in the same sector with AI ratings